Detailed Information

Cited 0 time in webofscience Cited 0 time in scopus
Metadata Downloads

Stereotactic body radiotherapy using helical tomotherapy for hepatocellular carcinoma: clinical outcome and dosimetric comparison of Hi-ART vs. Radixact

Authors
Bae, Sun HyunCho, Kwang HwanJung, Jae HongKim, Young SeokKim, Sang GyuneYoo, Jeong-JuLee, Jae MyungLee, Min HeeLim, Sung Hee
Issue Date
Nov-2022
Publisher
AME Publishing Company
Keywords
Hepatocellular carcinoma; helical tomotherapy (HT); Hi-ART system; Radixact; stereotactic body radiotherapy (SBRT)
Citation
Translational Cancer Research
Journal Title
Translational Cancer Research
URI
https://scholarworks.bwise.kr/sch/handle/2021.sw.sch/21859
DOI
10.21037/tcr-22-1565
ISSN
2218-676X
2219-6803
Abstract
<bold>Background</bold>: Helical tomotherapy (HT), a unique rotational dose delivery machine, has been updated from Hi-ART to Radixact. We retrospectively evaluated the treatment outcomes of stereotactic body radiotherapy (SBRT) using HT for hepatocellular carcinoma (HCC) and compared the dosimetric details of Hi-ART and Radixact. <bold>Methods</bold>: Between April 2014 and November 2020, 28 patients with HCC were treated with SBRT using HT for a cure at Soonchunhyang University College of Medicine, Bucheon. According to the Barcelona Clinic Liver Cancer classification, 9 patients had stage 0 disease, 12 had stage A, 4 had stage B, and 3 had stage C. The tumor size ranged from 1 cm to 8 cm (median, 2 cm). The SBRT dose ranged from 40 to 60 Gy (median, 48 Gy) with 4 fractions. Twenty-three patients were treated with Hi-ART and 5 patients were treated with Radixact. To compare the dosimetric parameters between Hi-ART and Radixact, we created treatment plans with the same constraints, pitch, modulation factor, and field width for the same patient in pairs.<bold>Results</bold>: The median follow-up time from the date of SBRT administration was 24 months (range, 3-67 months). The local failure-free survival and intrahepatic failure-free survival rates were 96% and 58% at 1 year, 84% and 36% at 2 years, and 76% and 18% at 3 years, respectively. The overall survival rate was 93% at 1 year, 93% at 2 years, and 53% at 3 years, respectively. When the paired treatment plans were reviewed, the beam-on time and intermediate dose-spillage were found to be significantly reduced in Radixact than Hi-ART (P<0.001). With regard to normal organ sparing, the irradiated dose to the total liver, normal liver, heart, and kidney was significantly lower with Radixact (P<0.001).<bold>Conclusions</bold>: SBRT using HT for HCC showed favorable treatment outcomes. Radixact, the latest version, physically improved treatment efficiency by reducing treatment time and provided better organ sparing than Hi-ART.
Files in This Item
There are no files associated with this item.
Appears in
Collections
College of Medicine > Department of Radiology > 1. Journal Articles
College of Medicine > Department of Internal Medicine > 1. Journal Articles
College of Medicine > Department of General Surgery > 1. Journal Articles
College of Medicine > Department of Radiation Oncology > 1. Journal Articles

qrcode

Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.

Related Researcher

Researcher Lee, Min Hee photo

Lee, Min Hee
College of Medicine (Department of Radiology)
Read more

Altmetrics

Total Views & Downloads

BROWSE